Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration‐resistant prostate cancer: Real‐world experience in the Southeast Asian cohort

It is of much interest to understand the efficacy of abiraterone acetate (AA) in routine clinical practice. We assessed the clinical outcome of AA in patients with metastatic castration‐resistant prostate cancer (mCRPC) and determined clinical factors associated with AA treatment duration in real‐wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jasmine, Amantakul, Akara, Shariff, Nisha, Lojanapiwat, Bannakij, Alip, Adlinda, Ong, Teng Aik, Thevarajah, Shankaran, Ahmayuddin, Firdaus, Mathew, Adeline, Sriplakich, Supon, Vuthiwong, Jaraspong, Chong, Flora Li Tze, Saad, Marniza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333845/
https://www.ncbi.nlm.nih.gov/pubmed/32374087
http://dx.doi.org/10.1002/cam4.3101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333845/
https://www.ncbi.nlm.nih.gov/pubmed/32374087
http://dx.doi.org/10.1002/cam4.3101

Ejemplares similares